About 3.6 mln Medicare beneficiaries could be eligible for Wegovy coverage, study shows

About 3.6 million overweight or obese patients with heart conditions insured under the U.S. Medicare program could be eligible for coverage of Novo Nordisk's (NOVOb.CO) weight-loss drug Wegovy, a study published by Kaiser Family Foundation (KFF) showed on Wednesday.